Takeda Obtains Rights To Develop HPV Vaccine In Japan
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical obtained Oct. 13 worldwide exclusive rights to develop and market human papillomavirus vaccine developed by Japan's National Institute for Infectious Disease